Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis.

ABSTRACT:

Introduction

In light of the clinically meaningful results of the PI3K inhibitors in PIK3CA-mutated metastatic breast cancer (BC) patients, the reliable identification of PIK3CA mutations is of outmost importance. However, lack of evidence on the optimal site and timing of assessment, presence of temporal heterogeneity and analytical factors pose several challenges in clinical routine. We aimed to study the discordance rates of PIK3CA mutational status between primary and matched metastatic tumors.

Methods

A systematic literature search was performed in three different databases (Embase, Pubmed, Web of Science) and-upon screening-a total of 25 studies reporting PIK3CA mutational status both on primary breast tumors and their matched metastases were included in this meta-anal

SUBMITTER: Rosin J 

PROVIDER: S-EPMC10361863 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature